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Developmental control of CFTR: from bioinformatics to novel therapeutic approaches
This report adds significantly to our existing knowledge regarding miRNA regulation of CFTR [5] [6] [7] [8] [9] [10] 13] and the developing field of miR-based CFTR therapeutics [15] . The data confirms previous studies implicating miR-145 and miR-101 as important modulators of CFTR expression [5, 6, 8, 9] and build on these by demonstrating how MBBOs based on these miRNAs can affect CFTR gene expression and CFTR protein function. The authors suggest that the MBBOs may be developed as tools for CFTR correction in people with CF.
Indeed this is an appealing option given that MBBOs are less likely to have off-target effects compared to some other miRNA inhibition strategies [reviewed in 16].
Although there are a series of novel findings from this paper, the work also raises a number of important questions for further investigation. The CF lung is inherently associated with microbial colonisation. Whether infection impacts upon the newly described transcriptional and post-transcriptional mechanisms controlling CFTR expression remains elusive. This will be particularly important for the further development of the MBBOs as therapeutics for CF. Previous studies have reported how infection and inflammation affect the expression of miRNAs, including those that regulate CFTR [9, 13] . This suggests that higher than normal levels of MBBOs may be required to ensure an inhibitory effect on endogenous miRNA activity. Nonetheless it will be a very exciting development when miRNA- restricted to miRNA-mediated effects [17] , miR-101 in particular is known to be increased by cigarette smoke extracts (CSE) and directly impacts on CFTR expression [8] . Finally, it is becoming increasingly evident that dysfunctional CFTR as a result of cigarette smoking can contribute to the pathophysiology of a range of extrapulmonary disease conditions, such as 4 chronic pancreatitis, male infertility and cachexia [18] . Expanding upon the findings from airway epithelial cells reported here into non-lung cells that express CFTR may yield novel therapies for these disease conditions beyond CF. 
